A retrospective clinical study on the prognosis and incidence of fractures between calcimimetics users and non-users in dialysis patients with achievement of PTH management target value

A retrospective clinical study on the prognosis and incidence of fractures between calcimimetics users and non-users in patients on hemodialysis using dialyzers with beta2-microglobulin clearance of more than 70 mL/min and on online hemodialfiltration with achievement of PTH management target value - Influence of prognosis and fracture incidence between calcimimetics users and non-users in HD using dialyzers with beta2-microglobulin clearance of more than 70 mL/min and OHDF

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055838

Enrollment

500

Registered

2025-01-03

Start date

2024-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with end-stage kidney disease undergoing hemodialysis and online hemodiafiltration

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients on maintenance hemodialysis or online hemodialysis as of July 1, 2017

Exclusion criteria

Exclusion criteria: 1 Use of dialyzers with beta2-microgloburln clearance below 70 mL/min 2 Missing data for covariates at study entry 3 Dialysis conditionssuch as dialysis method and membrane material between April 1, 2017 and June 30, 2017, which are different from those as of July 1, 2017 4 Blood purification methods other than hemodialysis and online hemodiafiltration 5 Dialysis frequency below 3 sessions per week or dialysis time below 3 hour per session 6 Pregnant or lactating patients 7 Patients with below 60pg/mL or over PTH 241pg/mL

Design outcomes

Primary

Measure	Time frame
2-year all-cause mortality	—

Secondary

Measure	Time frame
2-year incidence of fractures	—

Countries

Japan

Contacts

Public ContactManabu Tashiro

Social medical corporation Kawashimakai Kawashima Hospital Department of Nephrology

m.tashiro@khg.or.jp0886310110

Outcome results